AGÕæÈ˹ٷ½

STOCK TITAN

[S-8] CytomX Therapeutics, Inc. Employee Benefit Plan Registration

Filing Impact
(No impact)
Filing Sentiment
(Neutral)
Form Type
S-8
Rhea-AI Filing Summary

CytomX Therapeutics (CTMX) filed a Form S-8 on 7 Aug 2025 to register 4,381,320 additional common shares for issuance under its Amended & Restated 2015 Equity Incentive Plan. The statement incorporates eleven prior S-8 filings and updates only the exhibit section (legal opinion, auditor consent, revised plan documents).

The company is classified as an accelerated filer and a smaller reporting company. Shares will be issued as option grants, RSUs or other awards vest and are exercised; no immediate cash proceeds are expected. Although the filing does not include financial results, the newly registered shares expand the equity pool, enabling continued employee compensation but creating potential dilution for existing shareholders. All required signatures, powers of attorney and fee calculations are provided.

CytomX Therapeutics (CTMX) ha depositato un Modulo S-8 il 7 agosto 2025 per registrare 4.381.320 azioni ordinarie aggiuntive da emettere nell'ambito del suo Piano di Incentivi Azionari Modificato e Ristabilito del 2015. La dichiarazione incorpora undici precedenti depositi S-8 e aggiorna solo la sezione degli allegati (parere legale, consenso del revisore, documenti del piano revisionati).

La società è classificata come accelerated filer e smaller reporting company. Le azioni saranno emesse man mano che le opzioni, le RSU o altri premi maturano e vengono esercitati; non sono previsti proventi in contanti immediati. Sebbene il deposito non includa risultati finanziari, le nuove azioni registrate ampliano il pool azionario, permettendo la continuità nella retribuzione dei dipendenti ma comportando una possibile diluizione per gli azionisti esistenti. Sono forniti tutte le firme richieste, le procure e i calcoli delle commissioni.

CytomX Therapeutics (CTMX) presentó un Formulario S-8 el 7 de agosto de 2025 para registrar 4,381,320 acciones ordinarias adicionales para su emisión bajo su Plan de Incentivos de Acciones Enmendado y Restablecido de 2015. La declaración incorpora once presentaciones previas de S-8 y actualiza únicamente la sección de anexos (opinión legal, consentimiento del auditor, documentos revisados del plan).

La compañía está clasificada como presentador acelerado y compañía con reporte reducido. Las acciones se emitirán a medida que se otorguen opciones, RSU u otros premios y se ejerzan; no se esperan ingresos inmediatos en efectivo. Aunque la presentación no incluye resultados financieros, las acciones recién registradas amplían el grupo de acciones, permitiendo la continuidad en la compensación de empleados pero creando una posible dilución para los accionistas existentes. Se proporcionan todas las firmas requeridas, poderes notariales y cálculos de tarifas.

CytomX Therapeutics (CTMX)ëŠ� 2025ë…� 8ì›� 7ì¼ì— 수정 ë°� ìž¬ì •ë¹„ëœ 2015ë…� ì£¼ì‹ ì¸ì„¼í‹°ë¸Œ 계íšì—� ë”°ë¼ ì¶”ê°€ë¡� 4,381,320ì£� 보통ì£�ë¥� 등ë¡í•˜ê¸° 위해 Form S-8ì� 제출했습니다. ì� 성명서는 ì´ì „ì� 11ê±´ì˜ S-8 제출ì� í¬í•¨í•˜ë©°, 전시 섹션(법률 ì˜ê²¬ì„�, ê°ì‚¬ì� ë™ì˜ì„�, 수정ë� ê³„íš ë¬¸ì„œ)ë§� ì—…ë°ì´íŠ¸í•©ë‹ˆë‹�.

ÐëŒì‚¬µç� ê°€ì†� ì‹ ê³ ìž�(accelerated filer) ë°� 소규ëª� ë³´ê³  회사(smaller reporting company)ë¡� 분류ë©ë‹ˆë‹�. 주ì‹ì€ 옵션 ë¶€ì—�, RSU ë˜ëŠ” 기타 ë³´ìƒì� ì·¨ë“ë˜ê³  행사ë¨ì— ë”°ë¼ ë°œí–‰ë� 예정ì´ë©°, 즉ê°ì ì¸ 현금 수ìµì€ 예ìƒë˜ì§€ 않습니다. 제출서ì—ëŠ� 재무 결과가 í¬í•¨ë˜ì–´ 있지 않지ë§�, 새로 등ë¡ë� 주ì‹ì€ ì£¼ì‹ í’€ì� 확장하여 ì§ì› ë³´ìƒì� ì§€ì†í•  ìˆ� 있게 하며 기존 주주ì—게 잠재ì � í¬ì„ 효과ë¥� 초래í•� ìˆ� 있습니다. 모든 í•„ìš”í•� 서명, 위임ìž� ë°� 수수ë£� 계산ì� 제공ë©ë‹ˆë‹�.

CytomX Therapeutics (CTMX) a déposé un formulaire S-8 le 7 août 2025 pour enregistrer 4 381 320 actions ordinaires supplémentaires à émettre dans le cadre de son Plan d'Incitation en Actions modifié et révisé de 2015. La déclaration intègre onze dépôts S-8 antérieurs et ne met à jour que la section des annexes (avis juridique, consentement de l'auditeur, documents révisés du plan).

L'entreprise est classée comme déposant accéléré et petite société déclarant. Les actions seront émises à mesure que les options, les RSU ou autres récompenses seront acquises et exercées ; aucun produit en espèces immédiat n'est attendu. Bien que le dépôt n'inclue pas de résultats financiers, les actions nouvellement enregistrées élargissent le pool d'actions, permettant la continuité de la rémunération des employés mais créant une dilution potentielle pour les actionnaires existants. Toutes les signatures requises, procurations et calculs des frais sont fournis.

CytomX Therapeutics (CTMX) reichte am 7. August 2025 ein Formular S-8 ein, um 4.381.320 zusätzliche Stammaktien zur Ausgabe im Rahmen seines geänderten und neu gefassten Aktienanreizplans von 2015 zu registrieren. Die Erklärung umfasst elf frühere S-8-Einreichungen und aktualisiert nur den Anhang-Bereich (Rechtsgutachten, Zustimmung des Wirtschaftsprüfers, überarbeitete Planunterlagen).

Das Unternehmen ist als beschleunigter Einreicher (accelerated filer) und kleiner berichtspflichtiger Konzern (smaller reporting company) klassifiziert. Die Aktien werden ausgegeben, wenn Optionszuteilungen, RSUs oder andere Auszeichnungen vesten und ausgeübt werden; es werden keine sofortigen Bareinnahmen erwartet. Obwohl die Einreichung keine Finanzergebnisse enthält, erweitert die neu registrierte Aktienanzahl den Aktienpool, ermöglicht eine fortgesetzte Mitarbeitervergütung, kann aber zu einer potenziellen Verwässerung für bestehende Aktionäre führen. Alle erforderlichen Unterschriften, Vollmachten und Gebührenberechnungen sind beigefügt.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine S-8 registers 4.38 M shares; minimal immediate financial impact, modest dilution risk.

This Form S-8 is administrative, enlarging CytomX’s employee equity pool by roughly 4.4 million shares. Because issuance occurs over time as awards vest, near-term cash flow and earnings are unaffected. The filing signals management’s continued reliance on stock-based compensation to attract and retain talent—typical for a clinical-stage biotech. Current shareholders face incremental dilution; at a recent 96 M basic shares outstanding (not disclosed here but in last 10-Q), the pool equates to ~4.5% potential dilution, which is within sector norms. No change to strategic outlook or capitalization structure beyond this.

TL;DR: Governance neutral; plan already approved, filing merely adds shares.

The Amended & Restated 2015 Plan was previously adopted by shareholders, so this filing only implements that authorization. Exhibits include standard attorney and auditor consents, maintaining compliance. Power-of-attorney language is routine. No red flags around board oversight or compensation policy emerge from the document.

CytomX Therapeutics (CTMX) ha depositato un Modulo S-8 il 7 agosto 2025 per registrare 4.381.320 azioni ordinarie aggiuntive da emettere nell'ambito del suo Piano di Incentivi Azionari Modificato e Ristabilito del 2015. La dichiarazione incorpora undici precedenti depositi S-8 e aggiorna solo la sezione degli allegati (parere legale, consenso del revisore, documenti del piano revisionati).

La società è classificata come accelerated filer e smaller reporting company. Le azioni saranno emesse man mano che le opzioni, le RSU o altri premi maturano e vengono esercitati; non sono previsti proventi in contanti immediati. Sebbene il deposito non includa risultati finanziari, le nuove azioni registrate ampliano il pool azionario, permettendo la continuità nella retribuzione dei dipendenti ma comportando una possibile diluizione per gli azionisti esistenti. Sono forniti tutte le firme richieste, le procure e i calcoli delle commissioni.

CytomX Therapeutics (CTMX) presentó un Formulario S-8 el 7 de agosto de 2025 para registrar 4,381,320 acciones ordinarias adicionales para su emisión bajo su Plan de Incentivos de Acciones Enmendado y Restablecido de 2015. La declaración incorpora once presentaciones previas de S-8 y actualiza únicamente la sección de anexos (opinión legal, consentimiento del auditor, documentos revisados del plan).

La compañía está clasificada como presentador acelerado y compañía con reporte reducido. Las acciones se emitirán a medida que se otorguen opciones, RSU u otros premios y se ejerzan; no se esperan ingresos inmediatos en efectivo. Aunque la presentación no incluye resultados financieros, las acciones recién registradas amplían el grupo de acciones, permitiendo la continuidad en la compensación de empleados pero creando una posible dilución para los accionistas existentes. Se proporcionan todas las firmas requeridas, poderes notariales y cálculos de tarifas.

CytomX Therapeutics (CTMX)ëŠ� 2025ë…� 8ì›� 7ì¼ì— 수정 ë°� ìž¬ì •ë¹„ëœ 2015ë…� ì£¼ì‹ ì¸ì„¼í‹°ë¸Œ 계íšì—� ë”°ë¼ ì¶”ê°€ë¡� 4,381,320ì£� 보통ì£�ë¥� 등ë¡í•˜ê¸° 위해 Form S-8ì� 제출했습니다. ì� 성명서는 ì´ì „ì� 11ê±´ì˜ S-8 제출ì� í¬í•¨í•˜ë©°, 전시 섹션(법률 ì˜ê²¬ì„�, ê°ì‚¬ì� ë™ì˜ì„�, 수정ë� ê³„íš ë¬¸ì„œ)ë§� ì—…ë°ì´íŠ¸í•©ë‹ˆë‹�.

ÐëŒì‚¬µç� ê°€ì†� ì‹ ê³ ìž�(accelerated filer) ë°� 소규ëª� ë³´ê³  회사(smaller reporting company)ë¡� 분류ë©ë‹ˆë‹�. 주ì‹ì€ 옵션 ë¶€ì—�, RSU ë˜ëŠ” 기타 ë³´ìƒì� ì·¨ë“ë˜ê³  행사ë¨ì— ë”°ë¼ ë°œí–‰ë� 예정ì´ë©°, 즉ê°ì ì¸ 현금 수ìµì€ 예ìƒë˜ì§€ 않습니다. 제출서ì—ëŠ� 재무 결과가 í¬í•¨ë˜ì–´ 있지 않지ë§�, 새로 등ë¡ë� 주ì‹ì€ ì£¼ì‹ í’€ì� 확장하여 ì§ì› ë³´ìƒì� ì§€ì†í•  ìˆ� 있게 하며 기존 주주ì—게 잠재ì � í¬ì„ 효과ë¥� 초래í•� ìˆ� 있습니다. 모든 í•„ìš”í•� 서명, 위임ìž� ë°� 수수ë£� 계산ì� 제공ë©ë‹ˆë‹�.

CytomX Therapeutics (CTMX) a déposé un formulaire S-8 le 7 août 2025 pour enregistrer 4 381 320 actions ordinaires supplémentaires à émettre dans le cadre de son Plan d'Incitation en Actions modifié et révisé de 2015. La déclaration intègre onze dépôts S-8 antérieurs et ne met à jour que la section des annexes (avis juridique, consentement de l'auditeur, documents révisés du plan).

L'entreprise est classée comme déposant accéléré et petite société déclarant. Les actions seront émises à mesure que les options, les RSU ou autres récompenses seront acquises et exercées ; aucun produit en espèces immédiat n'est attendu. Bien que le dépôt n'inclue pas de résultats financiers, les actions nouvellement enregistrées élargissent le pool d'actions, permettant la continuité de la rémunération des employés mais créant une dilution potentielle pour les actionnaires existants. Toutes les signatures requises, procurations et calculs des frais sont fournis.

CytomX Therapeutics (CTMX) reichte am 7. August 2025 ein Formular S-8 ein, um 4.381.320 zusätzliche Stammaktien zur Ausgabe im Rahmen seines geänderten und neu gefassten Aktienanreizplans von 2015 zu registrieren. Die Erklärung umfasst elf frühere S-8-Einreichungen und aktualisiert nur den Anhang-Bereich (Rechtsgutachten, Zustimmung des Wirtschaftsprüfers, überarbeitete Planunterlagen).

Das Unternehmen ist als beschleunigter Einreicher (accelerated filer) und kleiner berichtspflichtiger Konzern (smaller reporting company) klassifiziert. Die Aktien werden ausgegeben, wenn Optionszuteilungen, RSUs oder andere Auszeichnungen vesten und ausgeübt werden; es werden keine sofortigen Bareinnahmen erwartet. Obwohl die Einreichung keine Finanzergebnisse enthält, erweitert die neu registrierte Aktienanzahl den Aktienpool, ermöglicht eine fortgesetzte Mitarbeitervergütung, kann aber zu einer potenziellen Verwässerung für bestehende Aktionäre führen. Alle erforderlichen Unterschriften, Vollmachten und Gebührenberechnungen sind beigefügt.

As filed with the Securities and Exchange Commission on August 7, 2025

Registration No. 333-   

 

 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

CytomX Therapeutics, Inc.

(Exact name of Registrant as specified in its charter)

 

 

 

Delaware   27-3521219
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)

151 Oyster Point Blvd., Suite 400

South San Francisco, CA 94080

(Address of Principal Executive Offices) (Zip Code)

 

 

CytomX Therapeutics, Inc. Amended and Restated 2015 Equity Incentive Plan

(Full Title of the Plan)

 

 

Sean A. McCarthy, D.Phil.

President and Chief Executive Officer

CytomX Therapeutics, Inc.

151 Oyster Point Blvd., Suite 400

South San Francisco, CA 94080

(650) 515-3185

(Name and address of agent for service)

(Telephone number, including area code, of agent for service)

 

 

Copies to:

Mark V. Roeder, Esq.

John C. Williams, Esq.

Latham & Watkins LLP

140 Scott Drive

Menlo Park, California 94025

(650) 328-4600

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 

Proposed sale to take place as soon after the effective date of the

registration statement as awards under the plans are exercised and/or vest.

 

 
 


EXPLANATORY NOTE

This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 4,381,320 shares of the Registrant’s common stock issuable under the following employee benefit plan for which Registration Statements of the Registrant on Form S-8 (File Nos. 333-207694, 333-209992, 333-215795, 333-223491, 333-229916, 333-236711, 333-253452, 333-263321, 333-270869, 333-277819 and 333-285594) are effective: the CytomX Therapeutics, Inc. Amended and Restated 2015 Equity Incentive Plan, as a result of the amendment and restatement of such plan, which added 4,381,320 shares of common stock.

INCORPORATION BY REFERENCE OF CONTENTS OF

REGISTRATION STATEMENT ON FORM S-8

Pursuant to Instruction E of Form S-8, the contents of the Registration Statements on Form S-8 filed with the Securities and Exchange Commission on October 30, 2015 (File No. 333-207694), March 7, 2016 (File No. 333-209992), January 27, 2017 (File No. 333-215795), March 7, 2018 (File No. 333-223491), February 27, 2019 (File No. 333-229916), February 27, 2020 (File No. 333-236711), February 24, 2021 (File No. 333-253452), March 4, 2022 (File No. 333-263321), March 27, 2023 (333-270869), March  11, 2024 (333-277819) and March 6, 2025 (File No. 333-285594) are incorporated by reference herein; except for Item 8 which is being updated by this Registration Statement.

Item 8. Exhibits

 

         Incorporated by Reference        
Exhibit
Number
 

Exhibit Description

   Form      Date      Number     Filed
Herewith
 
4.1   Amended and Restated Certificate of Incorporation.      8-K        5/17/2024        3.1    
4.2   Amended and Restated Bylaws.      8-K        3/22/2024        3.1    
4.3   Form of Common Stock Certificate.      S-1/A        9/28/2015        4.1    
4.4   Registration Rights Agreement dated as of September 29, 2017 by and between CytomX Therapeutics, Inc. and Amgen, Inc.      10-Q        11/7/2017        4.4    
5.1   Opinion of Latham & Watkins LLP.              X  
23.1   Consent of Independent Registered Public Accounting Firm.              X  
23.2   Consent of Latham & Watkins LLP (included in Exhibit 5.1).              X  
24.1   Power of Attorney. Reference is made to the signature page to the Registration Statement.              X  
99.1(a)#   CytomX Therapeutics, Inc. Amended and Restated 2015 Equity Incentive Plan.      8-K        6/13/2025        10.1    
99.1(b)#   Form of Option Award Notice under the CytomX Therapeutics, Inc. Amended and Restated 2015 Equity Incentive Plan.      10-Q        11/23/2015        10.4    
99.1(c)#   Form of Early Exercise Option Award Notice under the CytomX Therapeutics, Inc. Amended and Restated 2015 Equity Incentive Plan.      10-Q        11/23/2015        10.5    
99.1(d)#   Form of Restricted Share Unit Award Grant Notice and Agreement under the CytomX Therapeutics, Inc. Amended and Restated 2015 Equity Incentive Plan.      10-K        3/1/2022        10.3 (d)   
107   Filing Fee Table.              X  

 

#

Indicates management contract or compensatory plan.


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in South San Francisco, State of California, on August 7, 2025.

 

CytomX Therapeutics, Inc.

By:  

/s/ Sean A. McCarthy

 

Sean A. McCarthy, D.Phil.

 

President and Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Sean A. McCarthy and Christopher W. Ogden, and each of them, with full power of substitution and full power to act without the other, his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file this registration statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.

 

Signature

  

Title

  

Date

/s/ Sean A. McCarthy

Sean A. McCarthy, D.Phil.

   President, Chief Executive Officer and Chairman
(Principal Executive Officer)
   August 7, 2025

/s/ Christopher W. Ogden

Christopher W. Ogden

   Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)
   August 7, 2025

/s/ Matthew P. Young

Matthew P. Young

   Director    August 7, 2025

/s/ Alan Ashworth

Alan Ashworth, Ph.D. FRS

   Director    August 7, 2025

/s/ James R. Meyers

James R. Meyers

   Director    August 7, 2025

/s/ Elaine V. Jones

Elaine V. Jones, Ph.D.

   Director    August 7, 2025

/s/ Halley E. Gilbert

Halley E. Gilbert

   Director    August 7, 2025

/s/ Mani Mohindru

Mani Mohindru, Ph.D.

   Director    August 7, 2025

/s/ Zhen Su

Zhen Su, M.D.

   Director    August 7, 2025
Cytomx Therapeutics Inc

NASDAQ:CTMX

CTMX Rankings

CTMX Latest News

CTMX Latest SEC Filings

CTMX Stock Data

380.95M
163.48M
0.83%
49.81%
15.15%
Biotechnology
Pharmaceutical Preparations
United States
SOUTH SAN FRANCISCO